A new biomedical research study finds a transcription factor called Slug contributes to breast cell fitness by promoting efficient repair of DNA damage. The absence of Slug leads to unresolved DNA damage and accelerated aging of breast cells.
A new study argues against combined approach: Patients undergoing coordinated breast and gynecologic procedures had a significantly longer length of hospital stay, and higher complication, readmission, and reoperation rates compared with patients who underwent single site surgery.
Targeted drugs for breast and lung cancer could be used together to overcome resistance to treatment in several different tumour types, a new study shows. Scientists discovered that when the breast cancer drug palbociclib was combined with the lung cancer drug crizotinib, the two-drug combination was significantly more effective against cancer cells in the laboratory than either drug used on its own.
Previous US studies have found racial disparities in triple-negative breast cancer diagnoses, but few have looked beyond the scope of one state. To conduct a larger study, researchers analyzed all breast cancer cases diagnosed during 2010-14 from the United States Cancer Statistics database, a surveillance system of cancer registries with data representing 99 percent of the US population.
When doctors remove a tumor surgically or use targeted therapies, the cancer may appear to be gone. However, evidence suggests a tiny subpopulation of adaptable cancer cells can remain and circulate through the body to seed new metastasis in far-off locations. A collaborative research project has identified an entirely new class of molecules that shows promise in rooting out and killing those cancer stem cells.
Women who knew their BRCA+ status were diagnosed with earlier stage breast cancer, needed less chemotherapy, less extensive surgery, and had greater overall 5-year survival (98 percent vs. 74 percent).
New research that uncovers the mechanism behind the newest generation of cancer drugs is opening the door for better targeted therapy. PARP inhibitors are molecular targeted cancer drugs used to treat women with ovarian cancer who have the BRCA1 and BRCA2 gene mutations. The drugs are showing promise in late-stage clinical trials for breast cancer, prostate cancer and pancreatic cancer.